{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T06:26:22Z","timestamp":1794983182074,"version":"4.9.1"},"reference-count":103,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health (NIH), R16","award":["5R16GM149462-01"],"award-info":[{"award-number":["5R16GM149462-01"]}]},{"name":"National Institutes of Health (NIH), R16","award":["U54 MD007582"],"award-info":[{"award-number":["U54 MD007582"]}]},{"name":"National Institutes of Health (NIH), R16","award":["SUB00002097"],"award-info":[{"award-number":["SUB00002097"]}]},{"name":"National Institutes of Health (NIH), R16","award":["R01NS125016"],"award-info":[{"award-number":["R01NS125016"]}]},{"name":"National Institute on Minority Health and Health Disparities of the NIH","award":["5R16GM149462-01"],"award-info":[{"award-number":["5R16GM149462-01"]}]},{"name":"National Institute on Minority Health and Health Disparities of the NIH","award":["U54 MD007582"],"award-info":[{"award-number":["U54 MD007582"]}]},{"name":"National Institute on Minority Health and Health Disparities of the NIH","award":["SUB00002097"],"award-info":[{"award-number":["SUB00002097"]}]},{"name":"National Institute on Minority Health and Health Disparities of the NIH","award":["R01NS125016"],"award-info":[{"award-number":["R01NS125016"]}]},{"name":"Consortium for Medical Marijuana Clinical Outcomes Research","award":["5R16GM149462-01"],"award-info":[{"award-number":["5R16GM149462-01"]}]},{"name":"Consortium for Medical Marijuana Clinical Outcomes Research","award":["U54 MD007582"],"award-info":[{"award-number":["U54 MD007582"]}]},{"name":"Consortium for Medical Marijuana Clinical Outcomes Research","award":["SUB00002097"],"award-info":[{"award-number":["SUB00002097"]}]},{"name":"Consortium for Medical Marijuana Clinical Outcomes Research","award":["R01NS125016"],"award-info":[{"award-number":["R01NS125016"]}]},{"name":"National Institutes of Health (USA)","award":["5R16GM149462-01"],"award-info":[{"award-number":["5R16GM149462-01"]}]},{"name":"National Institutes of Health (USA)","award":["U54 MD007582"],"award-info":[{"award-number":["U54 MD007582"]}]},{"name":"National Institutes of Health (USA)","award":["SUB00002097"],"award-info":[{"award-number":["SUB00002097"]}]},{"name":"National Institutes of Health (USA)","award":["R01NS125016"],"award-info":[{"award-number":["R01NS125016"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>This study investigates the use of camel milk-derived exosomes (CMEs) as carriers for ARV-825, an anticancer agent targeting bromodomain-containing protein 4 (BRD4), in oral chemotherapy. CMEs were isolated and characterized, and ARV-825-loaded CME formulations were prepared and evaluated through various in vitro and in vivo tests. The ARV-825-CME formulation exhibited an entrapment efficiency of 42.75 \u00b1 5.05%, a particle size of 136.8 \u00b1 1.94 nm, and a zeta potential of \u221232.75 \u00b1 0.70 mV, ensuring stability and sustained drug release. In vitro studies showed a 5.4-fold enhancement in drug release kinetics compared to the free ARV-825 solution. Permeability studies indicated a 3.2-fold increase in apparent permeability, suggesting improved cellular uptake. Cytotoxicity assays demonstrated potent anticancer activity, with IC50 values decreasing by 1.5 to 2-fold in cancer cell lines SF8628 DIPG and H1975R (resistant to Osimertinib). In vivo pharmacokinetic studies in Sprague-Dawley rats revealed superior systemic absorption and bioavailability of ARV-825 from CMEs, with a 2.55-fold increase in plasma concentration and a 5.56-fold increase in AUC. Distribution studies confirmed absorption through the ileum. This research highlights the potential of CMEs as a promising delivery platform for ARV-825, enhancing its therapeutic efficacy and offering a novel approach to cancer treatment.<\/jats:p>","DOI":"10.3390\/pharmaceutics16081070","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T09:29:41Z","timestamp":1723714181000},"page":"1070","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Unlocking the Potential of Camel Milk-Derived Exosomes as Novel Delivery Systems: Enhanced Bioavailability of ARV-825 PROTAC for Cancer Therapy"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1852-6548","authenticated-orcid":false,"given":"Aakash","family":"Nathani","sequence":"first","affiliation":[{"name":"College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7809-4682","authenticated-orcid":false,"given":"Mounika","family":"Aare","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8228-7487","authenticated-orcid":false,"given":"Li","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Chemical and Biomedical Engineering, FAMU-FSU College of Engineering, Florida State University, Tallahassee, FL 32310, USA"},{"name":"Department of Biomedical Sciences, College of Medicine, Florida State University, Tallahassee, FL 32304, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Bagde","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-8519","authenticated-orcid":false,"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Chemical and Biomedical Engineering, FAMU-FSU College of Engineering, Florida State University, Tallahassee, FL 32310, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8611-9923","authenticated-orcid":false,"given":"Arun","family":"Rishi","sequence":"additional","affiliation":[{"name":"Department of Oncology, John D. Dingell VA Medical Center, Wayne State University School of Medicine, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9192-8143","authenticated-orcid":false,"given":"Mandip","family":"Singh","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1177\/2156587217696927","article-title":"Effective Medicinal Plant in Cancer Treatment, Part 2: Review Study","volume":"22","author":"Kooti","year":"2017","journal-title":"J. Evid.-Based Complement. Altern. Med."},{"key":"ref_2","unstructured":"CDC (2024, February 11). CDC Works 24\/7. Centers for Disease Control and Prevention, Available online: https:\/\/www.cdc.gov\/budget\/documents\/covid-19\/cdc-247-response-to-covid-19-fact-sheet.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_4","unstructured":"Research and Development in the Pharmaceutical Industry (2024, June 20). Congressional Budget Office, Available online: https:\/\/www.cbo.gov\/publication\/57126."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1158\/1078-0432.CCR-11-2938","article-title":"Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance","volume":"18","author":"Zamboni","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.drudis.2011.11.007","article-title":"Bridging solubility between drug discovery and development","volume":"17","author":"Di","year":"2012","journal-title":"Drug Discov. Today"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.tips.2012.02.001","article-title":"The Valley of Death in anticancer drug development: A reassessment","volume":"33","author":"Adams","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Tran, P., Pyo, Y.-C., Kim, D.-H., Lee, S.-E., Kim, J.-K., and Park, J.-S. (2019). Overview of the Manufacturing Methods of Solid Dispersion Technology for Improving the Solubility of Poorly Water-Soluble Drugs and Application to Anticancer Drugs. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11030132"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ctrv.2016.09.012","article-title":"Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique","volume":"50","author":"Sawicki","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2209419","DOI":"10.1002\/adfm.202209419","article-title":"Biopolymer Nanovehicles for Oral Delivery of Natural Anticancer Agents","volume":"33","author":"Falsafi","year":"2023","journal-title":"Adv. Funct. Mater."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bhalani, D.V., Nutan, B., Kumar, A., and Singh Chandel, A.K. (2022). Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics. Biomedicines, 10.","DOI":"10.3390\/biomedicines10092055"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1773-2247(12)50081-X","article-title":"Oral delivery of chemotherapeutic agents: Background and potential of drug delivery systems for colon delivery","volume":"22","author":"Schoener","year":"2012","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"El Masri, A.E.R., Tobler, C., Willemijn, B., Von Bueren, A.O., Ansari, M., and Samer, C.F. (2023). Case report: Hepatotoxicity and nephrotoxicity induced by methotrexate in a paediatric patient, what is the role of precision medicine in 2023?. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1130548"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","article-title":"Progressing nanotechnology to improve targeted cancer treatment: Overcoming hurdles in its clinical implementation","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1039\/D4NA00086B","article-title":"Cutting-edge approaches for targeted drug delivery in breast cancer: Beyond conventional therapies","volume":"6","author":"Chaudhari","year":"2024","journal-title":"Nanoscale Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm.2017.125","article-title":"Shedding light on the cell biology of extracellular vesicles","volume":"19","author":"Raposo","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1586\/epr.09.17","article-title":"Exosomes: Proteomic insights and diagnostic potential","volume":"6","author":"Simpson","year":"2009","journal-title":"Expert Rev. Proteom."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"216243","DOI":"10.1016\/j.canlet.2023.216243","article-title":"Exosomal delivery of cannabinoids against cancer","volume":"566","author":"Kaur","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.7150\/thno.52570","article-title":"Engineering exosomes for targeted drug delivery","volume":"11","author":"Liang","year":"2021","journal-title":"Theranostics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.4155\/fmc-2018-0417","article-title":"Exosome Manufacturing Status","volume":"11","author":"Whitford","year":"2019","journal-title":"Future Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Antes, T.J., Middleton, R.C., Luther, K.M., Ijichi, T., Peck, K.A., Liu, W.J., Valle, J., Echavez, A.K., and Marb\u00e1n, E. (2018). Targeting extracellular vesicles to injured tissue using membrane cloaking and surface display. J. Nanobiotechnol., 16.","DOI":"10.1186\/s12951-018-0388-4"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.canlet.2015.10.020","article-title":"Bovine milk-derived exosomes for drug delivery","volume":"371","author":"Munagala","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100797","DOI":"10.1016\/j.ajps.2023.100797","article-title":"Milk-derived exosomes as a promising vehicle for oral delivery of hydrophilic biomacromolecule drugs","volume":"18","author":"Li","year":"2023","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3168\/jds.S0022-0302(73)85292-0","article-title":"Further Evidence of Plasma Membrane Material in Skim Milk","volume":"56","author":"Plantz","year":"1973","journal-title":"J. Dairy Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/bs.acc.2015.12.005","article-title":"Chapter Four\u2014Tumor-Derived Exosomes and Their Role in Cancer Progression","volume":"Volume 74","author":"Makowski","year":"2016","journal-title":"Advances in Clinical Chemistry"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Rashidi, M., Bijari, S., Khazaei, A.H., Shojaei-Ghahrizjani, F., and Rezakhani, L. (2022). The role of milk-derived exosomes in the treatment of diseases. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.1009338"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Shaban, A.M., Raslan, M., Sharawi, Z.W., Abdelhameed, M.S., Hammouda, O., El-Masry, H.M., Elsayed, K.N.M., and El-Magd, M.A. (2023). Antibacterial, Antifungal, and Anticancer Effects of Camel Milk Exosomes: An In Vitro Study. Vet. Sci., 10.","DOI":"10.3390\/vetsci10020124"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1177\/1534735418786000","article-title":"Therapeutic Effect of Camel Milk and Its Exosomes on MCF7 Cells In Vitro and In Vivo","volume":"17","author":"Badawy","year":"2018","journal-title":"Integr. Cancer Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cellimm.2019.02.001","article-title":"Emerging roles of and therapeutic strategies targeting BRD4 in cancer","volume":"337","author":"White","year":"2019","journal-title":"Cell. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Liao, X., Qian, X., Zhang, Z., Tao, Y., Li, Z., Zhang, Q., Liang, H., Li, X., Xie, Y., and Zhuo, R. (2021). ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.753119"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Hajmirza, A., Emadali, A., Gauthier, A., Casasnovas, O., Gressin, R., and Callanan, M.B. (2018). BET Family Protein BRD4: An Emerging Actor in NF\u03baB Signaling in Inflammation and Cancer. Biomedicines, 6.","DOI":"10.3390\/biomedicines6010016"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12935-021-01908-w","article-title":"BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting \u201cUndruggable\u201d Myc-pathway genes","volume":"21","author":"Wu","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bbrc.2018.03.184","article-title":"AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo","volume":"499","author":"Xu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.bbagrm.2014.03.011","article-title":"The bromodomain: From epigenome reader to druggable target","volume":"1839","author":"Sanchez","year":"2014","journal-title":"Biochim. Biophys. Acta (BBA) Gene Regul. Mech."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.18632\/aging.102910","article-title":"ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma","volume":"12","author":"He","year":"2020","journal-title":"Aging"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Fu, Y., Saraswat, A., Wei, Z., Agrawal, M.Y., Dukhande, V.V., Reznik, S.E., and Patel, K. (2021). Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13071005"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1039\/C9FO01914F","article-title":"Camel milk exosomes modulate cyclophosphamide-induced oxidative stress and immuno-toxicity in rats","volume":"10","author":"Ibrahim","year":"2019","journal-title":"Food Funct."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Nathani, A., Sun, L., Khan, I., Aare, M., Bagde, A., Li, Y., and Singh, M. (2024). Combined Role of Interleukin-15 Stimulated Natural Killer Cell-Derived Extracellular Vesicles and Carboplatin in Osimertinib-Resistant H1975 Lung Cancer Cells with EGFR Mutations. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16010083"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Thane, K.E., Davis, A.M., and Hoffman, A.M. (2019). Improved methods for fluorescent labeling and detection of single extracellular vesicles using nanoparticle tracking analysis. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-48181-6"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1083\/jcb.201601085","article-title":"Exosomes mediate cell contact-independent ephrin-Eph signaling during axon guidance","volume":"214","author":"Gong","year":"2016","journal-title":"J. Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1038\/s41467-023-38785-y","article-title":"ExpressAnalyst: A unified platform for RNA-sequencing analysis in non-model species","volume":"14","author":"Liu","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"120943","DOI":"10.1016\/j.ijpharm.2021.120943","article-title":"Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models","volume":"607","author":"Patel","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.xphs.2020.01.010","article-title":"The Role of Self-Nanoemulsifying Drug Delivery Systems of CDODA-Me in Sensitizing Erlotinib-Resistant Non\u2013Small Cell Lung Cancer","volume":"109","author":"Nottingham","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.biochi.2022.12.008","article-title":"The role of Cannabidiol and tetrahydrocannabivarin to overcome doxorubicin resistance in MDA-MB-231 xenografts in athymic nude mice","volume":"208","author":"Kalvala","year":"2023","journal-title":"Biochimie"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"104967","DOI":"10.1016\/j.ejps.2019.104967","article-title":"Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems","volume":"137","author":"Boyd","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4155\/tde-2020-0079","article-title":"Challenges and Opportunities in the Delivery of Cancer Therapeutics: Update on Recent Progress","volume":"12","author":"Lorscheider","year":"2021","journal-title":"Ther. Deliv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2147\/IJN.S289443","article-title":"Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives","volume":"16","author":"Edis","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40262-015-0242-x","article-title":"Oral Bioavailability: Issues and Solutions via Nanoformulations","volume":"54","author":"Pathak","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Lou, J., Duan, H., Qin, Q., Teng, Z., Gan, F., Zhou, X., and Zhou, X. (2023). Advances in Oral Drug Delivery Systems: Challenges and Opportunities. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020484"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0304-3835(91)90082-S","article-title":"Inhibition of human renal cancer by monoclonal antibody targeted methotrexate-containing liposomes in an ascites tumor model","volume":"56","author":"Singh","year":"1991","journal-title":"Cancer Lett."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-3659(98)00174-6","article-title":"Stealth monensin liposomes as a potentiator of adriamycin in cancer treatment","volume":"59","author":"Singh","year":"1999","journal-title":"J. Control. Release"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1211\/0022357023772","article-title":"Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7\/dox) cell-line","volume":"56","author":"Shaik","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1007\/s11095-014-1377-4","article-title":"EphA2 Targeting Pegylated Nanocarrier Drug Delivery System for Treatment of Lung Cancer","volume":"31","author":"Patel","year":"2014","journal-title":"Pharm. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejpb.2016.08.006","article-title":"Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer","volume":"108","author":"Godugu","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1021\/acs.molpharmaceut.6b00187","article-title":"Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer","volume":"13","author":"Patel","year":"2016","journal-title":"Mol. Pharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/jnci\/85.4.292","article-title":"Potentiation of Antitumor Immunotoxins by Liposomal Monensin","volume":"85","author":"Griffin","year":"1993","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Berry, D., Ene, J., Nathani, A., Singh, M., Li, Y., and Zeng, C. (2024). Effects of Physical Cues on Stem Cell-Derived Extracellular Vesicles toward Neuropathy Applications. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030489"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Gebeyehu, A., Kommineni, N.D.G.M., and Singh, M.S. (2021). Role of Exosomes for Delivery of Chemotherapeutic Drugs. CRT, 38.","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2021036301"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1182\/blood.V130.Suppl_1.716.716","article-title":"BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825 Targets Both NOTCH1-MYC Regulatory Circuit and Leukemia-Microenvironment in T-ALL","volume":"130","author":"Piya","year":"2017","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1182\/blood.V128.22.748.748","article-title":"BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects","volume":"128","author":"Piya","year":"2016","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Finnegan, R.M., Elshazly, A.M., Patel, N.H., Tyutyunyk-Massey, L., Tran, T.H., Kumarasamy, V., Knudsen, E.S., and Gewirtz, D.A. (2023). The BET inhibitor\/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.966441"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Kaur, R., Singh, P., Kaur, A., Chaudhary, G., Choudhary, D., Kaur, P., and Sahu, S.K. (2024). OTX015 PROTACs: Emerging Novel Therapeutic Agents in Cancer Treatment. BIO Web Conf., 86.","DOI":"10.1051\/bioconf\/20248601038"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-016-0362-2","article-title":"Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: Role of cMYC-IRF4-miR-125b interplay","volume":"9","author":"Abruzzese","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_67","first-page":"5728","article-title":"BRD4 degrader ARV-825 produces long-lasting loss of BRD4 protein and exhibits potent efficacy against cholangiocarcinoma cells","volume":"11","author":"Lu","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1021\/acs.jmedchem.6b01816","article-title":"Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression","volume":"61","author":"Zhou","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1158\/0008-5472.CAN-16-2622","article-title":"Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer","volume":"77","author":"Bai","year":"2017","journal-title":"Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1555419","DOI":"10.1080\/20013078.2018.1555419","article-title":"Quality of extracellular vesicle images by transmission electron microscopy is operator and protocol dependent","volume":"8","author":"Rikkert","year":"2019","journal-title":"J. Extracell. Vesicles"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Doyle, L.M., and Wang, M.Z. (2019). Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis. Cells, 8.","DOI":"10.3390\/cells8070727"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Martins, T.S., Catita, J., Rosa, I.M., da Cruz e Silva, A.B., and Henriques, A.G. (2018). Exosome isolation from distinct biofluids using precipitation and column-based approaches. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0198820"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.crfs.2022.11.002","article-title":"Bovine milk exosomes affected proliferation of macrophages under hypoxia","volume":"5","author":"Matic","year":"2022","journal-title":"Curr. Res. Food Sci."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"El-kattawy, A.M., Algezawy, O., Alfaifi, M.Y., Noseer, E.A., Hawsawi, Y.M., Alzahrani, O.R., Algarni, A., Kahilo, K.A., and El-Magd, M.A. (2021). Therapeutic potential of camel milk exosomes against HepaRG cells with potent apoptotic, anti-inflammatory, and anti-angiogenesis effects for colostrum exosomes. Biomed. Pharmacother., 143.","DOI":"10.1016\/j.biopha.2021.112220"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Nakashima, Y., Miyagi-Shiohira, C., Noguchi, H., and Omasa, T. (2018). The Healing Effect of Human Milk Fat Globule-EGF Factor 8 Protein (MFG-E8) in A Rat Model of Parkinson\u2019s Disease. Brain Sci., 8.","DOI":"10.3390\/brainsci8090167"},{"key":"ref_76","first-page":"2601394","article-title":"Milk Fat Globule-Epidermal Growth Factor-Factor 8 Reverses Lipopolysaccharide-Induced Microglial Oxidative Stress","volume":"2019","author":"Li","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1074\/jbc.M307513200","article-title":"Peptidoglycan Recognition Protein Tag7 Forms a Cytotoxic Complex with Heat Shock Protein 70 in Solution and in Lymphocytes","volume":"279","author":"Sashchenko","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"24490","DOI":"10.1074\/jbc.M001239200","article-title":"Mammalian Peptidoglycan Recognition Protein Binds Peptidoglycan with High Affinity, Is Expressed in Neutrophils, and Inhibits Bacterial Growth","volume":"275","author":"Liu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"21724","DOI":"10.1074\/jbc.M115.639732","article-title":"Tag7 (PGLYRP1) in Complex with Hsp70 Induces Alternative Cytotoxic Processes in Tumor Cells via TNFR1 Receptor","volume":"290","author":"Yashin","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_80","first-page":"98","article-title":"The unique medicinal properties of camel products: A review of the scientific evidence","volume":"11","author":"Alhaider","year":"2016","journal-title":"J. Taibah Univ. Med. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Sedykh, S., Kuleshova, A., and Nevinsky, G. (2020). Milk Exosomes: Perspective Agents for Anticancer Drug Delivery. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186646"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Nizamudeen, Z.A., Xerri, R., Parmenter, C., Suain, K., Markus, R., Chakrabarti, L., and Sottile, V. (2021). Low-Power Sonication Can Alter Extracellular Vesicle Size and Properties. Cells, 10.","DOI":"10.3390\/cells10092413"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2015.03.033","article-title":"Exosomes as drug delivery vehicles for Parkinson\u2019s disease therapy","volume":"207","author":"Haney","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/aps.2017.12","article-title":"Engineering exosomes as refined biological nanoplatforms for drug delivery","volume":"38","author":"Luan","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.nano.2015.10.012","article-title":"Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells","volume":"12","author":"Kim","year":"2016","journal-title":"Nanomedicine"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Timofeeva, A.M., Paramonik, A.P., Sedykh, S.S., and Nevinsky, G.A. (2023). Milk Exosomes: Next-Generation Agents for Delivery of Anticancer Drugs and Therapeutic Nucleic Acids. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210194"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.nano.2017.03.001","article-title":"Milk-derived exosomes for oral delivery of paclitaxel","volume":"13","author":"Agrawal","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/17425255.2024.2366390","article-title":"Recent advances in cell-based in vitro models for predicting drug permeability across brain, intestinal, and pulmonary barriers","volume":"20","author":"Eltanameli","year":"2024","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_89","first-page":"620","article-title":"Rational Use of in Vitro P-glycoprotein Assays in Drug Discovery","volume":"299","author":"Polli","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1700082","DOI":"10.1002\/mnfr.201700082","article-title":"Human milk exosomes and their microRNAs survive digestion in vitro and are taken up by human intestinal cells","volume":"61","author":"Liao","year":"2017","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1701050","DOI":"10.1002\/mnfr.201701050","article-title":"Exosomal MicroRNAs in Milk from Mothers Delivering Preterm Infants Survive in Vitro Digestion and Are Taken Up by Human Intestinal Cells","volume":"62","author":"Kahn","year":"2018","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2005.05.016","article-title":"Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts","volume":"106","author":"Song","year":"2005","journal-title":"J. Control. Release"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ejpb.2010.09.002","article-title":"In vitro evaluation of liposomes containing bio-enhancers for the oral delivery of macromolecules","volume":"76","author":"Parmentier","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_94","unstructured":"Pellot, J.E., and De Jesus, O. (2024, June 21). Diffuse Intrinsic Pontine Glioma, StatPearls [Internet], Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560640\/."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12032-023-01954-6","article-title":"Chemotherapy: How to reduce its adverse effects while maintaining the potency?","volume":"40","author":"Brianna","year":"2023","journal-title":"Med. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21608\/kvmj.2022.233090","article-title":"Camel milk exosomes had a selective anticancer effect on PANC1 cells and a proliferative effect on H6c7 cells","volume":"20","author":"Ali","year":"2022","journal-title":"Kafrelsheikh Vet. Med. J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1208\/s12248-017-0154-9","article-title":"Exosomes for the Enhanced Tissue Bioavailability and Efficacy of Curcumin","volume":"19","author":"Aqil","year":"2017","journal-title":"AAPS J."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Chen, L., Wang, L., Zhu, L., Xu, Z., Liu, Y., Li, Z., Zhou, J., and Luo, F. (2022). Exosomes as Drug Carriers in Anti-Cancer Therapy. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.728616"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3945\/jn.115.218586","article-title":"The Intestinal Transport of Bovine Milk Exosomes Is Mediated by Endocytosis in Human Colon Carcinoma Caco-2 Cells and Rat Small Intestinal IEC-6 Cells","volume":"145","author":"Wolf","year":"2015","journal-title":"J. Nutr."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"C800","DOI":"10.1152\/ajpcell.00169.2015","article-title":"Human vascular endothelial cells transport foreign exosomes from cow\u2019s milk by endocytosis","volume":"310","author":"Kusuma","year":"2016","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jff.2017.05.009","article-title":"Milk miRNAs encapsulated in exosomes are stable to human digestion and permeable to intestinal barrier in vitro","volume":"34","author":"Rani","year":"2017","journal-title":"J. Funct. Foods"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.3168\/jds.2012-5489","article-title":"Bovine milk contains microRNA and messenger RNA that are stable under degradative conditions","volume":"95","author":"Izumi","year":"2012","journal-title":"J. Dairy Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"116166","DOI":"10.1016\/j.ejmech.2024.116166","article-title":"Annual review of PROTAC degraders as anticancer agents in 2022","volume":"267","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/8\/1070\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:37:14Z","timestamp":1760110634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/8\/1070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":103,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["pharmaceutics16081070"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16081070","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]}}}